Biotechnology company Eikon Therapeutics announced the initial closing of a $350.7 million Series D financing round that it will use to advance its clinical-stage programs. The new funding brings the ...
The analysis examined overall program counts as well as distribution by development stage, drug modality, and therapeutic area. Growth in early-stage development was observed across multiple countries ...
As we approach 2026,late-stage programs across key therapeutic areas are poised to reshape treatment paradigms. Driven by novel mechanisms, first-in-class targets and more convenient administration ...
Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three preclinical epigenomic controller programs including a collaboration with Novo ...
The last time I spoke about Prothena Corporation plc (PRTA), it was in a Seeking Alpha article entitled "Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place." I went ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results